Bicara Therapeutics BCAX Operating lease right-of-use assets amortization expense
Operating lease right-of-use assets amortization expense at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's operating lease right-of-use assets amortization expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's operating lease right-of-use assets amortization expense?
- Bicara Therapeutics (BCAX) reported operating lease right-of-use assets amortization expense of $273K in Q1 2026.
- How has Bicara Therapeutics's operating lease right-of-use assets amortization expense changed year-over-year?
- Bicara Therapeutics's operating lease right-of-use assets amortization expense increased by 97.8% year-over-year, from $138K to $273K.